Literature DB >> 28972127

Functional Characterization of 5-HT1B Receptor Drugs in Nonhuman Primates Using Simultaneous PET-MR.

Hanne D Hansen1, Joseph B Mandeville2, Christin Y Sander2, Jacob M Hooker2, Ciprian Catana2, Bruce R Rosen2, Gitte M Knudsen3,4.   

Abstract

In the present study, we used a simultaneous PET-MR experimental design to investigate the effects of functionally different compounds (agonist, partial agonist, and antagonist) on 5-HT1B receptor (5-HT1BR) occupancy and the associated hemodynamic responses. In anesthetized male nonhuman primates (n = 3), we used positron emission tomography (PET) imaging with the radioligand [11C]AZ10419369 administered as a bolus followed by constant infusion to measure changes in 5-HT1BR occupancy. Simultaneously, we measured changes in cerebral blood volume (CBV) as a proxy of drug effects on neuronal activity. The 5-HT1BR partial agonist AZ10419369 elicited a dose-dependent biphasic hemodynamic response that was related to the 5-HT1BR occupancy. The magnitude of the response was spatially overlapping with high cerebral 5-HT1BR densities. High doses of AZ10419369 exerted an extracranial tissue vasoconstriction that was comparable to the less blood-brain barrier-permeable 5-HT1BR agonist sumatriptan. By contrast, injection of the antagonist GR127935 did not elicit significant hemodynamic responses, even at a 5-HT1BR cerebral occupancy similar to the one obtained with a high dose of AZ10419369. Given the knowledge we have of the 5-HT1BR and its function and distribution in the brain, the hemodynamic response informs us about the functionality of the given drug: changes in CBV are only produced when the receptor is stimulated by the partial agonist AZ10419369 and not by the antagonist GR127935, consistent with low basal occupancy by endogenous serotonin.SIGNIFICANCE STATEMENT We here show that combined simultaneous positron emission tomography and magnetic resonance imaging uniquely enables the assessment of CNS active compounds. We conducted a series of pharmacological interventions to interrogate 5-HT1B receptor binding and function and determined blood-brain barrier passage of drugs and demonstrate target involvement. Importantly, we show how the spatial and temporal effects on brain hemodynamics provide information about pharmacologically driven downstream CNS drug effects; the brain hemodynamic response shows characteristic dose-related effects that differ depending on agonistic or antagonistic drug characteristics and on local 5-HT1B receptor density. The technique lends itself to a comprehensive in vivo investigation and understanding of drugs' effects in the brain.
Copyright © 2017 the authors 0270-6474/17/3710671-08$15.00/0.

Entities:  

Keywords:  5-HT1B; PET-MR imaging; nonhuman primates; pharmacology

Mesh:

Substances:

Year:  2017        PMID: 28972127      PMCID: PMC5666586          DOI: 10.1523/JNEUROSCI.1971-17.2017

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  44 in total

Review 1.  Positron emission tomography molecular imaging for drug development.

Authors:  Paul M Matthews; Eugenii A Rabiner; Jan Passchier; Roger N Gunn
Journal:  Br J Clin Pharmacol       Date:  2012-02       Impact factor: 4.335

2.  GABA concentrations in the human anterior cingulate cortex predict negative BOLD responses in fMRI.

Authors:  Georg Northoff; Martin Walter; Rolf F Schulte; Johannes Beck; Ulrike Dydak; Anke Henning; Heinz Boeker; Simone Grimm; Peter Boesiger
Journal:  Nat Neurosci       Date:  2007-11-04       Impact factor: 24.884

Review 3.  GR127935: a potent and selective 5-HT1D receptor antagonist.

Authors:  M Skingle; D T Beattie; D I Scopes; S J Starkey; H E Connor; W Feniuk; M B Tyers
Journal:  Behav Brain Res       Date:  1996       Impact factor: 3.332

Review 4.  Challenges in developing drugs for primary headaches.

Authors:  Henrik Winther Schytz; Richard Hargreaves; Messoud Ashina
Journal:  Prog Neurobiol       Date:  2016-01-02       Impact factor: 11.685

5.  Toward implementing an MRI-based PET attenuation-correction method for neurologic studies on the MR-PET brain prototype.

Authors:  Ciprian Catana; Andre van der Kouwe; Thomas Benner; Christian J Michel; Michael Hamm; Matthias Fenchel; Bruce Fischl; Bruce Rosen; Matthias Schmand; A Gregory Sorensen
Journal:  J Nucl Med       Date:  2010-09       Impact factor: 10.057

6.  High-resolution imaging of brain 5-HT 1B receptors in the rhesus monkey using [11C]P943.

Authors:  Nabeel Nabulsi; Yiyun Huang; David Weinzimmer; Jim Ropchan; James J Frost; Timothy McCarthy; Richard E Carson; Yu-Shin Ding
Journal:  Nucl Med Biol       Date:  2009-12-01       Impact factor: 2.408

7.  Cocaine enhancement of the action of 5-hydroxytryptamine in rat cingulate cortex in vitro.

Authors:  E Tanaka; R A North
Journal:  Neurosci Lett       Date:  1993-11-26       Impact factor: 3.046

8.  Vasoconstriction in human isolated middle meningeal arteries: determining the contribution of 5-HT1B- and 5-HT1F-receptor activation.

Authors:  Z Razzaque; M A Heald; J D Pickard; L Maskell; M S Beer; R G Hill; J Longmore
Journal:  Br J Clin Pharmacol       Date:  1999-01       Impact factor: 4.335

9.  Acute serotonin 2A receptor blocking alters the processing of fearful faces in the orbitofrontal cortex and amygdala.

Authors:  Bettina Hornboll; Julian Macoveanu; James Rowe; Rebecca Elliott; Olaf B Paulson; Hartwig R Siebner; Gitte M Knudsen
Journal:  J Psychopharmacol       Date:  2013-07-02       Impact factor: 4.153

10.  A possible mechanism of the nucleus accumbens and ventral pallidum 5-HT1B receptors underlying the antidepressant action of ketamine: a PET study with macaques.

Authors:  H Yamanaka; C Yokoyama; H Mizuma; S Kurai; S J Finnema; C Halldin; H Doi; H Onoe
Journal:  Transl Psychiatry       Date:  2014-01-07       Impact factor: 6.222

View more
  3 in total

1.  In vivo biased agonism at 5-HT1A receptors: characterisation by simultaneous PET/MR imaging.

Authors:  Benjamin Vidal; Sylvain Fieux; Jérôme Redouté; Marjorie Villien; Frédéric Bonnefoi; Didier Le Bars; Adrian Newman-Tancredi; Nicolas Costes; Luc Zimmer
Journal:  Neuropsychopharmacology       Date:  2018-07-06       Impact factor: 7.853

Review 2.  Advances in simultaneous PET/MR for imaging neuroreceptor function.

Authors:  Christin Y Sander; Hanne D Hansen; Hsiao-Ying Wey
Journal:  J Cereb Blood Flow Metab       Date:  2020-03-13       Impact factor: 6.200

Review 3.  Methods for Quantifying Neurotransmitter Dynamics in the Living Brain With PET Imaging.

Authors:  Jenny Ceccarini; Heather Liu; Koen Van Laere; Evan D Morris; Christin Y Sander
Journal:  Front Physiol       Date:  2020-07-21       Impact factor: 4.566

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.